AYLA Ayala Pharmaceuticals Inc.
Upcoming Catalysts
| Drug | Stage | Catalyst Date |
|---|---|---|
|
AL101 (ACCURACY)
Adenoid cystic carcinoma
|
Phase 2
Phase 2
|
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
|
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
AL101
T-cell acute lymphoblastic leukemia
|
Phase 2
Phase 2
|
Phase 2 trial to commence 2H 2021.
|
|
AL102
Desmoid tumors
|
Phase 2
Phase 2
|
Phase 2 trial to be initiated 1H 2021.
|
|
AL101 TENACITY
Triple negative breast cancer
|
Phase 2
Phase 2
|
Phase 2 trial to commence 2H 2020.
|
Latest News
-
View Full Article Hide Full Article
REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that Ayala management will participate in two upcoming virtual investor conferences:
- H.C. Wainwright & Co. 6th Annual Israel Conference: Thursday, November 12, 2020 at 8:30 am ET.
- Jefferies Virtual London Healthcare Conference: Fireside chat - Thursday, November 19, 2020 at 6:45 pm ET.
A live webcast of each event may be accessed by visiting the Events & Presentations section of Ayala's website at ir.ayalapharma.com. An archived replay of each webcast will be available on the website for 90 days following the presentations.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala's lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. For more information, visit www.ayalapharma.com.Contacts:
Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
[email protected]Ayala Pharmaceuticals:
+1-857-444-0553
[email protected]
-
View Full Article Hide Full Article
REHOVOT, Israel and WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will host a virtual Key Opinion Leader (KOL) event to review new interim data presented from the ongoing Phase 2 ACCURACY study of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harbouring Notch activating mutations at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The event will take place on Friday, September 18, 2020 at 8:00 am ET.
The event will feature presentations from Ayala management and KOL, Dr. Alan L. Ho, M.D., Ph.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center and a lead investigator in the ACCURACY trial.
A live webcast of the event will be available on the Events & Presentations section of the Ayala website at ir.ayalapharma.com. To access the call, please dial 833-519-1339 (United States & Canada) or 914-800-3901 (international) and reference the conference ID 3995105. A replay of the webcast and accompanying slides will be available on the Ayala website for 90 days following the event.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala's lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. For more information, visit www.ayalapharma.com.Contacts:
Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
[email protected]Ayala Pharmaceuticals:
+1-857-444-0553
[email protected] -
View Full Article Hide Full Article
REHOVOT, Israel and WILMINGTON, Del., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that Ayala management will present at two upcoming investor conferences:
- H.C. Wainwright & Co. 22nd Annual Global Healthcare Conference: Tuesday, September 15, 2020 at 12:30 pm ET.
- Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit: Monday, September 21, 2020 at 1:40 pm ET.
A live webcast of each presentation may be accessed by visiting the Events & Presentations section of Ayala's website at ir.ayalapharma.com. An archived replay of each webcast will be available on the website for 90 days following the presentations.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala's lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. For more information, visit www.ayalapharma.com.Contacts:
Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
[email protected]Ayala Pharmaceuticals:
+1-857-444-0553
[email protected] -
View Full Article Hide Full Article
REHOVOT, Israel and WILMINGTON, Del., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (the Company or Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced the appointment of Vered Bisker-Leib, Ph.D., to its Board of Directors, joining as a member of the Audit and Compensation Committees.
"Vered is a significant addition to our Board of Directors as we continue to grow Ayala as a public company and we are thrilled to be able to tap into her deep strategic, operational and financial expertise," said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. "Through her leadership and strategic experience gained as Chief Operating Officer at Compass Therapeutics and at Bristol-Meyer Squibb's strategic transaction group, Vered will offer a valuable perspective as we continue to further advance our pipeline of novel therapies for genetically defined cancers to patients in need."
"I am thrilled to join Ayala's Board of Directors at such an exciting time in the company's life cycle," said Vered Bisker-Leib, Ph.D. "Ayala's novel pipeline offers a unique approach to difficult to treat cancers where gamma secretase inhibition provides targeted clinical benefit. I look forward to working closely with the Board and management team to bring Ayala closer to realizing its goals of developing and commercializing small molecule therapeutics for rare and aggressive genetically defined cancers."
Dr. Bisker-Leib brings over 17 years of experience in operational and business development experience in the biotechnology industry. Currently, Dr. Bisker-Leib serves as Chief Operation Officer of Compass Therapeutics, Inc. where she is responsible for finance, business development, strategy, alliance management, legal affairs, operations, investor relations and public relations. Prior to joining the company in 2017 as its Chief Business Officer, she was an Executive-In-Residence at Atlas Ventures, advising portfolio companies. Previously, she was the Chief Business Officer of Cydan, where she co-founded several biotechnology companies including, Imara, Inc., and the Global Head of Business Development of the Cardiovascular and Metabolic franchises at Bristol-Myers Squibb. Dr. Bisker-Leib holds a Ph.D. in Chemical Engineering and an MBA from the University of Massachusetts, Amherst.
"Ayala has reached significant milestones in 2020 and is poised to continue on this trajectory," said David Sidransky, M.D., Chairman of the Board. "We very much look forward to working with Vered as Ayala continues to execute across multiple upcoming milestones."
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala's lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. For more information, visit www.ayalapharma.com.
Contacts:
Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
[email protected]Ayala Pharmaceuticals:
+1-857-444-0553
[email protected] -
View Full Article Hide Full Article
REHOVOT, Israel and WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that interim results from the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harbouring Notch activating mutations will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, being held September 19-September 21, 2020.
Oral presentation information is as follows:
Title: ACCURACY a Phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
Session Title: Mini Oral Presentation
Session Date and Time: September 18, 2020, 03:55 CEST
Presentation Number: 919MO
Presenter: Renata Ferrarotto, MD, MD Anderson Cancer CenterThe presentation will be available to registrants of the ESMO Virtual Congress 2020 at 03:55 CEST on September 18, 2020. The presentation will be archived under "Events and Presentations" in the Investors section of Ayala's website at ir.ayalapharma.com.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala's lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. For more information, visit www.ayalapharma.comContacts:
Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
[email protected]Ayala Pharmaceuticals:
+1-857-444-0553
[email protected]